Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Pomalidomide (Pomalyst) in combo with Dexamethasone and Bortezomib for Multiple Myeloma 
(Final Recommendation Issued as of September 18, 2019)

Daratumumab (Darzalex) in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma 
(Notification to Implement Issued as of September 16, 2019)

Trifluridine-Tipiracil (Lonsurf) Resubmission for Metastatic Colorectal Cancer 
(Notification to Implement Issued as of September 16, 2019)

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer 
(Pending Submission as of September 16, 2019)

Cabozantinib (Cabometyx) for Hepatocellular Carcinoma
(Pending Submission as of September 16, 2019)

Brentuximab Vedotin (Adcetris) for Peripheral T-Cell Lymphoma
(Pending Submission as of September 10, 2019)

Atezolizumab (Tecentriq) Advanced or Metastatic Triple-Negative Breast Cancer
(Pending Submission as of September 4, 2019)

Find a Drug Review